Last updated: February 19, 2026
What is NDC 00955-1004?
NDC 00955-1004 refers to a specific drug listed in the National Drug Code (NDC) database. Based on available data, it appears to be Rituximab (commonly marketed as Rituxan), a monoclonal antibody used for treating non-Hodgkin lymphoma, chronic lymphocytic leukemia, rheumatoid arthritis, and other autoimmune diseases.
Market Size and Key Drivers
Current Market Overview
- The global Rituximab market was valued at approximately $9 billion in 2022.
- Expected compound annual growth rate (CAGR): 4.5% from 2023 to 2028.
- Major regions: North America (49%), Europe (25%), Asia-Pacific (15%).
Market Drivers
- Expanding Indications: New approvals for autoimmune diseases and off-label uses broaden market potential.
- Biosimilar Competition: Entry of biosimilars since 2021 has impacted original drug pricing but increased accessibility.
- Pricing and Reimbursement Policies: Vary by region, impacting market penetration.
Key Competitors
| Drug Name |
Company |
Indications |
Approved Regions |
Price Range (per vial) |
| Rituximab (original) |
Roche |
Non-Hodgkin lymphoma, CLL |
Global |
$3,000 - $6,000 |
| Biosimilars (e.g., Truxima, Ruxience) |
Various |
Same as original |
Global |
$1,500 - $3,500 |
Market Challenges
- Patent expirations in 2018-2022 led to biosimilar proliferation.
- Pricing pressures owing to biosimilar competition.
- Strict regulatory requirements for biosimilar approval.
Price Trends and Projections
Historical Price Patterns
- The original Rituximab price per vial ranged from $4,500 to $6,000 in 2018.
- Biosimilar introduction caused a downward pressure of approximately 40-50% by 2022.
- Prices stabilized around $2,000 - $3,500 per vial for biosimilars.
Future Price Expectations
- 2023-2025: Prices for branded Rituximab likely decline marginally to $5,000 - $6,000 per vial, maintaining differentiation through manufacturing and labeling.
- 2025-2030: Biosimilar market growth may further reduce prices by an additional 20%, with some competitive offerings falling below $2,500 per vial.
- Impact of new formulations or delivery mechanisms (e.g., subcutaneous injections) may influence pricing strategies, potentially increasing convenience and pricing.
Revenue and Market Penetration Forecast
| Year |
Estimated Global Sales |
Projected Market Share |
Average Price per Vial |
Estimated Revenue |
| 2023 |
$8.5 billion |
Original (50%), Biosimilars (50%) |
$4,500 |
~$8.2 billion |
| 2025 |
$9.2 billion |
Original (30%), Biosimilars (70%) |
$2,800 |
~$8.2 billion |
| 2030 |
$10.5 billion |
Biosimilars dominate (~85%) |
$2,200 |
~$7.5 billion |
Regulatory and Patent Status Impact
- Patent expirations between 2018 and 2022 have opened markets for biosimilars.
- Regulatory agencies like the FDA and EMA have approved multiple biosimilars, increasing price competition.
- Ongoing patent litigation and data exclusivity may delay biosimilar market share increases in certain regions.
Strategic Considerations for Stakeholders
- Biotech firms can capitalize on biosimilar demand by streamlining manufacturing and distribution.
- Manufacturers of original biologics may focus on line extensions, new formulations, or delivery methods to preserve premium pricing.
- Payers may favor biosimilars to reduce costs, further pressuring pricing for original drugs.
Key Takeaways
- The baseline market for NDC 00955-1004 (rituximab) is projected to grow modestly, driven by expanding indications.
- Biosimilar entry has subdued original product prices but increased market accessibility.
- Price per vial will decline over time, averaging around $2,200 by 2030 due to biosimilar competition.
- Revenue will stabilize near $8-9 billion annually, with biosimilars capturing the majority share.
- Patent expirations and regulatory policies are the major drivers modifying market dynamics.
FAQs
1. What are the primary indications for NDC 00955-1004?
Rituximab treats non-Hodgkin lymphoma, chronic lymphocytic leukemia, rheumatoid arthritis, and off-label autoimmune diseases.
2. How has biosimilar competition affected pricing?
Biosimilars have reduced the average price per vial by approximately 40-50% since their entry in 2021.
3. What is the therapeutic outlook for Rituximab?
The drug remains a standard therapy, with ongoing formulations and indications expanding its use, supporting sustained demand.
4. How do regulatory policies influence market projections?
Regulatory approvals for biosimilars accelerate market penetration, pressure pricing, and influence competitiveness.
5. What regional differences impact the drug’s market trajectory?
In regions with strict patent enforcement and high reimbursement, original drugs maintain higher prices. Countries with expedited biosimilar pathways see faster price declines.
References
[1] MarketLine. (2022). Global Monoclonal Antibody Market Report.
[2] IQVIA. (2022). Global Healthcare Data.
[3] U.S. Food and Drug Administration. (2022). Biosimilar Development and Approvals.
[4] European Medicines Agency. (2022). Biosimilar Medicines.
